Medical Updates

Optimal Glycemic Control for Diabetes in Developing Countries-Still a Long Way to go!

The glycemic control in type-2 diabetes mellitus (T2DM) patients in developing countries is suboptimal, revealed a recent real-world study conducted...

22 Jan, 2020

 
Email this page
SMBG may Improve Glycemic Control and Glycemic Variability in Non-Insulin-treated T2DM Patients

Type-2 diabetes mellitus (T2DM) patients who undertook structured self-monitoring of blood glucose (SMBG) paired with blood glucose testing...

20 Jan, 2020

 
Email this page
Ascertaining the Role of Autoimmunity in Diabetes Onset after 40 Years of Age

A recent study suggested that incident diabetes in adults has an element of autoimmune aetiology, making it necessary to re-evaluate the present sub...

13 Jan, 2020

 
Email this page
Youth Onset Diabetes - No More a Rare Entity in India!

A recent analysis of the Indian Council of Medical Research funded Registry of people with diabetes in India with Young age at onset (YDR registry...

08 Jan, 2020

 
Email this page

Key Trials

VERIFY: Early Vildagliptin and Metformin Combination Therapy Associated with Greater and Long-term Glycemic Durability vs. Metformin Monotherapy

Newly diagnosed type 2 diabetes mellitus patients treated with an early combination therapy of vildagliptin plus metformin experience greater...

Moderate Weight Loss following Diabetes Diagnosis May Reduce Long-term CVD Risk

The study demonstrates that a moderate weight loss (≥5%) in type-2 diabetes patients within a year of the disease diagnosis cuts down the risk of...

CREDENCE: Impact of Canagliflozin on Cardio-Renal Outcomes in T2DM Patients with CKD

According to the findings of the CREDENCE trial, canagliflozin rendered protection against renal and cardiovascular outcomes in type-2 diabetes...

SGLT2 Inhibitors for Prevention of CV and Renal Outcomes in T2DM Patients: Does the ASCVD Status Matter?

Findings of the study showed that SGLT2 inhibitors effectively reduce the risk of MACE, renal outcomes, and hospitalizations for HF in T2DM patients...

Patient Education

Diabetic Retinopathy

Diabetic retinopathy (DR) is the most common and most serious of the ocular complications of diabetes mellitus. This patient education leaflet on DR...

Diabetes Management During Ramadan

Fasting & feasting during Ramadan in diabetes patients is associated with altered glucose level which may lead to low or high blood sugar level....

Know More about Diabetes

Diabetes implies high blood sugar levels in blood. Find out more about the cause, risk factors and complications associated with this disease.

Yoga

The ancient science of yoga provides various health benefits to an individual. Know more about the ‘asanas’ that are beneficial for diabetes patients...

Our Publications

Mind Matters (Issue 3) - Role of Escitalopram in the Treatment of Comorbid Depression and Diabetes

The presence of depression in patients with diabetes mellitus is of vast importance, as it is usually associated with poor disease control, adverse...

Diabetes Management Series: Cholesterol

Most relevant information on management of dyslipidemia, a common comorbidity observed in diabetes patients, has been summarised in this document.

Drug Therapy for Management of Hyperglycaemia

Brief information on the treatment strategy and selection of oral antihyperglycemic agents in type 2 diabetes is summarised in this document.

Diabetes Management Series: Hypertension

Hypertension elevates the risk of micro-and macro-vascular complications in diabetes. Here is a summary on the BP treatment goals in diabetes...

Slide Library

Management of Diabetes during Ramadan

Fasting & feasting during Ramadan in diabetes patients is associated with increased risk of complications such as hypoglycemia, hyperglycemia,...

 
Email this page
Clinical Practice Recommendations: ADA 2014

This slide set summarizes the key 2014 clinical practice recommendations of the American Diabetes Association (ADA) on the screening, diagnosis and...

 
Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

 
Email this page
Treating Hypertension in Diabetics : Optimal Selection of Antihypertensive Therapy

Hypertension affects 20%-60% of diabetics. It substantially increases the risk of macrovascular and microvascular complications in diabetes. This...

 
Email this page

Poll

Which is your preferred DPP4 inhibitor for your type 2 diabetes patients with ESRD?
Sitagliptin
20% (4 votes)
Vildagliptin
25% (5 votes)
Linagliptin
50% (10 votes)
No specific choice
5% (1 vote)
Don’t prefer a DPP4 inhibitor
0% (0 votes)
Total votes: 20